Zobrazeno 1 - 10 of 8 158 pro vyhledávání: '"Lacy MQ"'
1
Report
Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma - updated results after 18-year follow-up.
Autor: Abdallah N; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Witzig TE; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Kumar SK; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Lacy MQ; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Hayman SR; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Dispenzieri A; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Roy V; Division of Hematology, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA., Gertz MA; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Bergsagel PL; Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA., Rajkumar SV; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. rajkumar.vincent@mayo.edu.
Publikováno v: Leukemia [Leukemia] 2024 May; Vol. 38 (5), pp. 1169-1171. Date of Electronic Publication: 2024 Feb 28.
Zobrazit plný text záznamu
2
Akademický článek
Lacy MQ, McCurdy AR. Pomalidomide. Blood. 2013;122(14):2305-2309.
Publikováno v: In Blood 26 June 2014 123(26):4153-4153
Zobrazit plný text záznamu
3
Akademický článek
Retreatment of multiple myeloma with previously refractory drugs.
Autor: Goel U; Division of Hematology, Mayo Clinic, Rochester, MN.; Department of Internal Medicine, Cleveland Clinic, Cleveland, OH., Charalampous C; Division of Hematology, Mayo Clinic, Rochester, MN., Kapoor P; Division of Hematology, Mayo Clinic, Rochester, MN., Binder M; Division of Hematology, Mayo Clinic, Rochester, MN., Buadi FK; Division of Hematology, Mayo Clinic, Rochester, MN., Dingli D; Division of Hematology, Mayo Clinic, Rochester, MN., Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, MN., Fonder A; Division of Hematology, Mayo Clinic, Rochester, MN., Gertz MA; Division of Hematology, Mayo Clinic, Rochester, MN., Gonsalves WI; Division of Hematology, Mayo Clinic, Rochester, MN., Hayman SR; Division of Hematology, Mayo Clinic, Rochester, MN., Hobbs MA; Division of Hematology, Mayo Clinic, Rochester, MN., Hwa YL; Division of Hematology, Mayo Clinic, Rochester, MN., Kourelis T; Division of Hematology, Mayo Clinic, Rochester, MN., Lacy MQ; Division of Hematology, Mayo Clinic, Rochester, MN., Leung N; Division of Hematology, Mayo Clinic, Rochester, MN., Lin Y; Division of Hematology, Mayo Clinic, Rochester, MN., Warsame RM; Division of Hematology, Mayo Clinic, Rochester, MN., Kyle RA; Division of Hematology, Mayo Clinic, Rochester, MN., Rajkumar SV; Division of Hematology, Mayo Clinic, Rochester, MN., Kumar SK; Division of Hematology, Mayo Clinic, Rochester, MN.
Publikováno v: Blood advances [Blood Adv] 2024 Dec 24; Vol. 8 (24), pp. 6321-6328.
Zobrazit plný text záznamu
5
Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis.
Autor: Visram A; Division of Hematology, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada.; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Vachon C; Division of Epidemiology, Mayo Clinic, Rochester, MN, USA., Baughn LB; Division of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN, USA.; Division of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Larson D; Division of Biostatistics, Mayo Clinic, Rochester, MN, USA., Smadbeck J; Division of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN, USA., Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kapoor P; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Lacy MQ; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gertz MA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Buadi FK; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hayman SR; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Dingli D; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kourelis T; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gonsalves W; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Warsame R; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Muchtar E; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Leung N; Division of Nephrology, Mayo Clinic, Rochester, MN, USA., Kyle RA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Rajkumar SV; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kumar S; Division of Hematology, Mayo Clinic, Rochester, MN, USA. kumar.shaji@mayo.edu.
Publikováno v: Leukemia [Leukemia] 2024 Aug; Vol. 38 (8), pp. 1865.
Zobrazit plný text záznamu
6
Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.
Autor: Vaxman I; Division of Hematology, Mayo Clinic, Rochester, MN, USA.; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel., Kumar SK; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Buadi F; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Lacy MQ; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Dingli D; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hwa Y; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Fonder A; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hobbs M; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hayman S; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kourelis T; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Warsame R; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Muchtar E; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Leung N; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kapoor P; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Grogan M; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA., Go R; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Lin Y; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gonsalves W; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Siddiqui M; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kyle RA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Rajkumar SV; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gertz MA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, MN, USA. dispenzieri.angela@mayo.edu.
Publikováno v: Leukemia [Leukemia] 2024 Aug; Vol. 38 (8), pp. 1866.
Zobrazit plný text záznamu
7
Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.
Autor: Visram A; Division of Hematology, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada.; Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA., Rajkumar SV; Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA., Kapoor P; Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA., Dispenzieri A; Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA., Lacy MQ; Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA., Gertz MA; Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA., Buadi FK; Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA., Hayman SR; Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA., Dingli D; Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA., Kourelis T; Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA., Gonsalves W; Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA., Warsame R; Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA., Muchtar E; Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA., Leung N; Division of Nephrology, Mayo Clinic Rochester, Rochester, MN, USA., Kyle RA; Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA., Kumar SK; Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA. kumar.shaji@mayo.edu.
Publikováno v: Leukemia [Leukemia] 2024 Aug; Vol. 38 (8), pp. 1862.
Zobrazit plný text záznamu
8
Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.
Autor: Abdallah N; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Murray D; Department of Laboratory, Medicine and Pathology, Rochester, MN, USA., Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kapoor P; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gertz MA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Lacy MQ; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hayman SR; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Buadi FK; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gonsalves W; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Muchtar E; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Leung N; Division of Hematology, Mayo Clinic, Rochester, MN, USA.; Division of Nephrology, Mayo Clinic, Rochester, MN, USA., Dingli D; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kourelis T; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Warsame R; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Binder M; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kyle RA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Rajkumar SV; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kumar S; Division of Hematology, Mayo Clinic, Rochester, MN, USA. kumar.shaji@mayo.edu.
Publikováno v: Leukemia [Leukemia] 2024 Aug; Vol. 38 (8), pp. 1864.
Zobrazit plný text záznamu
9
Akademický článek
A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL).
Autor: Visram A; Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada., Hayman SR; Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Dispenzieri A; Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Kapoor P; Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Lacy MQ; Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Gertz MA; Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Buadi FK; Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Dingli D; Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Warsame R; Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Kourelis T; Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Cook J; Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Binder M; Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Gonsalves W; Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Muchtar E; Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Leung N; Division of Nephrology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Roy V; Division of Hematology, Mayo Clinic, Jacksonville, Florida, USA., Rajkumar SV; Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Kumar S; Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Publikováno v: American journal of hematology [Am J Hematol] 2023 Aug; Vol. 98 (8), pp. 1277-1285. Date of Electronic Publication: 2023 Jun 19.
Zobrazit plný text záznamu
10
Akademický článek
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide.
Autor: Goel U; Division of Hematology, Mayo Clinic, Rochester, MN, USA.; Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA., Charalampous C; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kapoor P; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Binder M; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Buadi FK; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Dingli D; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Fonder A; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gertz MA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gonsalves WI; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hayman SR; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hobbs MA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hwa YL; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kourelis T; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Lacy MQ; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Leung N; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Lin Y; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Warsame RM; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kyle RA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Rajkumar SV; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kumar SK; Division of Hematology, Mayo Clinic, Rochester, MN, USA. Kumar.Shaji@mayo.edu.
Publikováno v: Blood cancer journal [Blood Cancer J] 2024 Mar 26; Vol. 14 (1), pp. 55. Date of Electronic Publication: 2024 Mar 26.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje